Human DNA topoisomerase I: An anticancer drug target present in human sarcomas

Human Pathology

Volumn 33, Issue 6, 2002, Pages 599-607

  Coleman, Landon W ^a,b   Rohr, L Ralph ^a,b   Bronstein, Igor B ^a,b   Holden, Joseph A ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

ALK; DNA topoisomerase I; DNA topoisomerase II alpha; P53; Sarcoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DISEASE MARKER; DRUG RESPONSE; DRUG SENSITIVITY; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PARAMETER; PROTEIN EXPRESSION; PROTEIN ISOLATION; SARCOMA; TUMOR CELL; TUMOR SUPPRESSOR GENE;

EID: 0036321137     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/hupa.2002.124911     Document Type: Article

References (36)

1. Clinical applications of the camptothecins
2. Irinotecan in the treatment of colorectal cancer: Clinical overview
3. Topotecan: Incorporating it into the treatment of solid tumors
4. Chemotherapy in soft tissue sarcoma: The Scandinavian Sarcoma experience
5. New agents in the treatment of soft-tissue sarcomas
6. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma
7. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients
8. Phase II study of topotecan (NSC 609 699) in patients with recurrent metastatic soft tissue sarcoma
9. Topoisomerase I intereacts with transcribed regions in Drosophila cells
10. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA
11. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA
12. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme
13. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin
14. Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I
15. Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin
16. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan
17. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: Correlation with DNA topoisomerase II-alpha and p 53 expression
18. DNA topoisomerase II-alpha as a proliferation marker in endocrine and other neoplasms
19. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
20. Resistance to apoptosis induced by topoisomerase I inhibitors in multidrug-resistant HL 60 leukemic cells
21. Molecular abnormalities of mdm 2 and p53 genes in adult soft tissue sarcomas
22. Nuclear immunoreactions of p 53 protein in soft tissue sarcomas
23. Prognosis is correlated with p 53 mutation type for soft tissue sarcoma patients
24. The p53 gene in soft tissue sarcomas: Prognostic value of DNA sequencing versus immunohistochemistry
25. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma
26. Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer
27. Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies
28. DNA topoisomerases as anticancer drug targets: From the laboratory to the clinic
29. Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax-embedded normal tissues and in ovarian carcinomas
30. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas
31. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
32. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors
33. Inflammatory fibrosarcoma: Update, reappraisal, and perspective on its place in the spectrum of inflammatory myofibroblastic tumors
34. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding
35. Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: A multivariate analysis of five antibodies
36. Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways